IRAK4-IN-20

SKU: orb1687329

Description

IRAK4-IN-20 is a potent, orally bioavailable IRAK4 inhibitor with an IC50 of 3.55 nM. It demonstrates anti-inflammatory and anticancer activities in research, supporting its investigation in models of diseases like ARDS, cancer, and autoimmune disorders through both in vitro and in vivo studies.

Research Area

Immunology & Inflammation, Signal Transduction

Key Properties

• CAS Number: 1931994-80-7
• MW: 450.45
• Purity: 98.09% (May vary between batches)
• Formula: C₂₂H₂₅F₃N₄O₃
• SMILES: C(C)(C)(O)C1=CC=2C(C=C1NC(=O)C=3N=C(C(F)(F)F)C=CC3)=CN(CCC(C)(C)O)N2
• Target: IRAK
• Solubility: DMSO:25 mg/mL (55.5 mM)

Bioactivity

• Target IC50:
  IRAK4:3.55 nM
• In Vivo:
  IRAK4-IN-20 (Compound BAY-1834845), administered orally at 150 mg/kg either once 30 minutes before or twice at 4 and 12 hours after LPS induction, significantly mitigated acute respiratory distress syndrome in 6–7-week-old female Balb/c mice models. This treatment markedly reduced inflammatory cell and neutrophil infiltration in bronchoalveolar lavage fluid (BALF), decreased total T cells, monocytes, and macrophages, and preserved the integrity of naïve lymphocytes and stromal cells, including endothelial cells, chondrocytes, and smooth muscle cells. Moreover, it more effectively regulated inflammation and innate immunity genes compared to Dexamethasone, demonstrating its potential as a therapeutic agent for ARDS.
  Read more...
• In Vitro:
  Compound BAY-1834845 (IRAK4-IN-20) at a concentration of 500 nM, effectively reduces the secretion of inflammatory cytokines when administered for 20 hours in an in vitro assay involving LPS-stimulated human peripheral blood mononuclear cells (PBMC) .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BAY 1834845, BAY1834845, BAY-1834845, IRAK4, IRAK4-IN-20

Compound Identifiers

PubChem CID

121364971